Apps

Photo: Ryan Albrey / Wikimedia Commons (CC BY 2.0)

Lynas posts record Q2 revenue, expands heavy REE

{"summary":"Lynas Rare Earths posted a record quarterly revenue of A$288.9 million for June 2026, up 70% year-on-year, as the company ramped its Mt Weld expansion and resolved bottlenecks at Kalgoorlie, with 3,481 tonnes of rare earth oxides produced. The market backdrop reflects a structural shift to geopolitically anchored pricing and supply diversification away from China, supported by heavy rare earths growth, new partnerships, and policy moves such as the G7 target to limit dependence on a single supplier.","summary_sources":"[\"https://grafa.com/en/news/australia/lynas-rare-earths-reaches-288-9m-revenue-in-june-quarter\", \"https://discoveryalert.com.au/lynas-rare-earths-q4-revenue-rise-pricing-shift-2026/\", \"https://www.fool.com.au/2026/07/22/lynas-rare-earths-june-quarter-earnings-break-records/\", \"https://kalkine.com.au/news/announcements/lynas-rare-earths-achieves-record-quarterly-revenue-of-a2889-million-on-heavy-rare-earth-expansion\"]}

6 sources

Photo: CRISIL / Wikimedia Commons (CC BY-SA 4.0)

Crisil Announces Amalgamation to Form PayMetrix, Pending Approvals

Crisil Limited announced the amalgamation of its wholly-owned subsidiaries Crisil Canada Inc. and Crisil PriceMetrix Inc. to form Crisil PriceMetrix Inc., aimed at streamlining operations with no change in shareholding and subject to regulatory approvals. The company posted strong Q2 and H1 FY26 results, declared an interim dividend of Rs 10 per share, and shared updated governance and investor presentations detailing GDP outlook and performance across its ratings, research, and analytics businesses.

12 sources

Photo: Léonce Fabre des Essarts / Wikimedia Commons (Public domain)

Alpha DaRT Pembrolizumab Combo Shows 100% Response

Alpha Tau Medical reported positive data from a single-center study of Alpha DaRT combined with pembrolizumab in elderly patients with locally advanced or metastatic head and neck cancer, achieving a 100% systemic objective response rate and an 18.2-month median overall survival with no serious Alpha DaRT-related adverse events. The results, presented at the AHNS conference in Boston, exceeded historical pembrolizumab benchmarks and support continued trials and the company’s strategic push in immuno-oncology, with analyst notes highlighting a Buy rating for DRTS.

7 sources

Photo: Americasroof (talk) / Wikimedia Commons (CC BY-SA 3.0)

Marsh & McLennan Q2 Revenue Up 6%

Marsh & McLennan reported Q2 2026 revenue of $7.4 billion, up 6%, with adjusted EPS of $2.96 (up 9%) as CEO John Doyle cited strong demand across risk, people, strategy and investments. The six‑month results showed revenue of $15.0 billion and adjusted EPS of $6.25, with Risk & Insurance Services posting $4.8 billion in quarterly revenue and consulting up 10%, while the company also expanded shareholder value via a 4.5 million share repurchase and a 10% dividend hike.

10 sources

Photo: Tyler Lahti / Wikimedia Commons (CC BY-SA 4.0)

Equifax reports $1.70B Q2 revenue, pursues Círculo acquisition

Equifax reported Q2 2026 revenue of $1.700 billion, about 11% higher year over year, with GAAP net income of $183.9 million and diluted EPS of $1.54, alongside adjusted diluted EPS of $2.25 and adjusted EBITDA of $552.1 million as it pushes AI-driven efficiency. The company also announced the acquisition of Círculo de Crédito in Mexico, lifted its AI-driven cost-reduction target to $150 million for 2026–2028, and maintained full-year guidance of about $6.71–$6.78 billion in revenue and $8.39–$8.69 in EPS, plus Q3 adj EPS guidance of $2.15–$2.25.

7 sources

Photo: Kurt Kaiser / Wikimedia Commons (CC0)

Arvind Fashions Reports 15.5% Revenue Growth, 12.5% EBITDA

Arvind Fashions reported a strong Q1 FY27, with revenue up about 15.5% to roughly ₹1,278-1,279 crore and EBITDA up around 19-20% to ₹160 crore, as margins expanded to about 12.5%. While net profit rose 11% to ₹28 crore, some updates noted a PAT decline due to lower other income, and investors reacted variably to the results.

9 sources

Gateley posts record revenue, CEO plans step down

Gateley reports a record FY26 revenue of £194.3 million and confirms chief executive Rod Waldie will step down in August 2026, with Martin Pike serving as interim CEO during the transition. The group also resets its dividend policy to a lower total payout of 5.3 pence per share for the year, including a final 2.0p, in pursuit of sustainable growth and improved margins.

5 sources

Photo: W.carter / Wikimedia Commons (CC BY 4.0)

Galliford Try Secures £9.5bn CPC Framework

Galliford Try has been appointed to the Crescent Purchasing Consortium Construction and Capital Works framework worth £9.5 billion, spanning all five regional lots across England, Wales and Scotland for up to eight years and covering education and wider public sector projects from new-builds to refurbishments. The appointment strengthens its position in UK public infrastructure and expands the visibility of future revenues through a steady pipeline of core contracts.

5 sources

CM.com reports 14% revenue, 55% EBITDA growth

CM.com posted stronger first half 2026 results, with Q2 revenue up around 14% year-on-year and EBITDA up 55%, alongside record messaging volumes and growth in ARR driven by HALO and the new Customer Context Platform. MedCap AB reported robust Q2 2026 growth, with net sales up 16% and EBITA up 38% (adjusted EBITA up 28%), supported by acquisitions such as Biopsafe and continued margin improvement in all segments.

7 sources

Photo: Ken Lund from Reno, Nevada, USA / Wikimedia Commons (CC BY-SA 2.0)

Wintrust Q2 Profit Rises to $225M

Wintrust Financial posted solid Q2 results with $225.3 million in net income and $3.30 per share on revenue of about $961 million, a year-over-year rise driven by loan and deposit growth. The bank also reported record first-half net income for 2026, driven by strong net interest income and ongoing balance-sheet expansion, and beat consensus estimates for quarterly earnings per share.

15 sources

Pulse

Pulse

hk.marketscreener.com

Recently covered

Lynas posts record Q2 revenue, expands heavy REE

Crisil Announces Amalgamation to Form PayMetrix, Pending Approvals

Alpha DaRT Pembrolizumab Combo Shows 100% Response

Marsh & McLennan Q2 Revenue Up 6%

Equifax reports $1.70B Q2 revenue, pursues Círculo acquisition

Arvind Fashions Reports 15.5% Revenue Growth, 12.5% EBITDA

Gateley posts record revenue, CEO plans step down

Galliford Try Secures £9.5bn CPC Framework

CM.com reports 14% revenue, 55% EBITDA growth

Wintrust Q2 Profit Rises to $225M